Marina Chiara Garassino

Stories

Lilly's olomorasib shows durable first-line activity in KRAS G12C lung cancer at ESMO

Argued first-line adoption by 2026 was unlikely without mature Phase 3 data

KRAS G12C-mutant non-small cell lung cancer has no approved first-line targeted therapy. Standard care is immunotherapy with or without chemotherapy, and most patients never reach second-line treatment, so the first choice carries a lot of weight.

Updated Oct 26